An observational study in Adenomyosis of Uterus, Implantation Failure and Infertility Female, sponsored by Vida Fertility Institute. Not yet recruiting at 3 sites in Spain. Open to female participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-10-21.
Sponsored by Vida Fertility Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.
This prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent implantation failure (RIF), defined as ≥2 failed transfers with high-quality blastocysts (≥BB Gardner in oocyte donation, or PGT-A confirmed euploid in autologous cycles).
The primary endpoint is the live birth rate (LBR) per embryo transfer. Secondary endpoints include clinical pregnancy rate, miscarriage rate, morphological response of adenomyosis (uterine volume and junctional zone [JZ] thickness assessed by standardised transvaginal ultrasound), and tolerability profile. The study also explores the optimal treatment duration (3 vs 6 months) as a sub-analysis based on morphological response at the month-3 visit.
The study is conducted at three centres of Vida Fertility Institute (Madrid, Alicante and San Sebastián, Spain). Sample size: n=30 patients. Study duration: 24 months.
BACKGROUND:
Current standard of care for adenomyosis prior to embryo transfer in RIF patients consists of GnRH agonist therapy (triptorelin depot) for 1-3 months, with or without letrozole. This approach requires intramuscular administration, is associated with intense vasomotor symptoms, and has a prolonged pharmacological residual effect (4-6 weeks) that complicates cycle planning. No prospective study has evaluated linzagolix in this specific clinical scenario.
DESIGN:
Prospective before-after case series. Each patient serves as her own historical control (prior failed transfers under standard care vs outcome after linzagolix treatment). Treatment duration (3 or 6 months) is determined by morphological response at the month-3 ultrasound visit. Treatment extension to 6 months is indicated if any of the following criteria are met at month 3: uterine volume reduction \<20% from baseline, JZ maximum ≥12 mm, JZ difference ≥5 mm, or serum estradiol >40 pg/ml indicating incomplete hypothalamic-pituitary-ovarian axis suppression. Endometrial preparation is initiated 7 days after the last dose of linzagolix.
ULTRASOUND PROTOCOL:
Standardised transvaginal ultrasound measurements at each visit: uterine volume (L x AP x T x 0.523 cm3), junctional zone maximum (mm), junctional zone minimum (mm) and junctional zone difference (mm). All measurements performed in strict sagittal plane with ≥7 MHz transvaginal probe.
VASOMOTOR SYMPTOM MANAGEMENT:
Standardised non-estrogenic supplementation protocol (Cimicifuga racemosa 20 mg, Remifemin) if EVA score ≥4 for hot flushes or insomnia. Suspended simultaneously with the last dose of linzagolix.
REGULATORY FRAMEWORK:
Observational study with medicinal products (EOMF) under Spanish Royal Decree 957/2020. Use of linzagolix in this indication is off-label. Study approved by CEIm del Hospital Clinico San Carlos, Madrid (ref. 26/769-O_M_SP, October 13, 2026)."
142 studies on the registry are indexed under Adenomyosis; 54 are open to participants now.
This study's planned enrollment of 30 is below the median of 200 across 57 observational studies indexed under Adenomyosis.
Browse Adenomyosis studies →This is the only study on the registry with Vida Fertility Institute as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Women aged 18 to 50 years with confirmed adenomyosis (transvaginal ultrasound or MRI) and recurrent implantation failure, defined as 2 or more failed embryo transfers with high-quality blastocysts (grade BB or above in oocyte donation cycles, or PGT-A confirmed euploid blastocysts in autologous cycles), attending Vida Fertility Institute centres in Madrid, Alicante and San Sebastian, Spain.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with confirmed adenomyosis and recurrent implantation failure (2 or more failed embryo transfers with high-quality blastocysts: grade BB or above in oocyte donation cycles, or PGT-A confirmed euploid in autologous cycles) receiving linzagolix 200 mg orally once daily for 3 to 6 months prior to embryo transfer. Treatment duration is determined at the month-3 visit based on morphological response (uterine volume reduction, junctional zone measurements) and serum estradiol levels (\>40 pg/ml indicating incomplete axis suppression). Endometrial preparation is initiated 7 days after the last dose of linzagolix.
Drug: Linzagolix 200 mg (Yselty)
Linzagolix 200 mg orally once daily for a minimum of 3 months, extendable to 6 months based on morphological response (uterine volume and junctional zone assessment) and serum estradiol levels (\>40 pg/ml) at the month-3 visit.O ff-label use for adenomyosis prior to embryo transfer.
Also known as: Yselty, GnRH receptor antagonist
Live Birth Rate (LBR) per embryo transfer
Proportion of embryo transfers resulting in the birth of a live neonate at or beyond 24 weeks of gestation.
Time frame: Up to 12 months after embryo transfer
Clinical Pregnancy Rate
Proportion of embryo transfers resulting in the presence of an intrauterine gestational sac with fetal heartbeat on transvaginal ultrasound at 6-7 weeks of gestation.
Time frame: 6-7 weeks after embryo transfer
Miscarriage Rate
Proportion of clinical pregnancies ending in spontaneous pregnancy loss before 22 weeks of gestation.
Time frame: Up to 22 weeks of gestation
Change in Uterine Volume
Change in uterine volume (cm3) measured by transvaginal ultrasound using the ellipsoid formula (L x AP x T x 0.523) from baseline to post-treatment.
Time frame: Baseline, month 3, month 6 (if applicable) and pre-transfer (approximately 3-7 months from baseline)
Change in Junctional Zone Maximum Thickness
Change in junctional zone (JZ) maximum thickness (mm) measured by standardised transvaginal ultrasound in strict sagittal plane from baseline to post-treatment.
Time frame: Baseline, month 3, month 6 (if applicable) and pre-transfer (approximately 3-7 months from baseline)
Incidence of Vasomotor Adverse Events
Proportion of patients reporting hot flushes, insomnia or other vasomotor symptoms, assessed using a visual analogue scale (EVA 0-10) at each visit.
Time frame: Monthly during treatment period (up to 6 months)
Serum estradiol levels
Serum estradiol levels (pg/ml) measured at baseline, month 1, month 3 and month 6 to assess degree of hypothalamic-pituitary-ovarian axis suppression during linzagolix treatment.
Time frame: Baseline, month 1, month 3, month 6 (if applicable).
Hepatic safety
Hepatic function parameters (ALT, AST, GGT and total bilirubin) measured at baseline, month 3 and month 6 to assess liver safety during linzagolix treatment.
Time frame: Baseline, month 3, month 6 (if applicable).
Plan to share: Undecided — Individual participant data will not be shared at this stage due to the small sample size and the need to protect patient privacy in accordance with the General Data Protection Regulation (GDPR, EU 2016/679) and Spanish Organic Law 3/2018 on Personal Data Protection. Anonymised aggregate data may be made available upon reasonable request following publication of the primary results.
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Jul 2028, 18 months later.
Of 31 observational studies under Adenomyosis, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29. This study's planned 18 months is below that.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Jan 2027, on Oct 21, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.